223 related articles for article (PubMed ID: 22119277)
1. [Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].
Dábague Guzmán J; Pedroza Granados J; Zúñiga Varga J
Reumatol Clin; 2011 Dec; 7 Suppl 3():S37-40. PubMed ID: 22119277
[TBL] [Abstract][Full Text] [Related]
2. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
Hoffman GS
Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
[No Abstract] [Full Text] [Related]
3. L44. Management of relapses in vasculitis.
Mouthon L
Presse Med; 2013 Apr; 42(4 Pt 2):619-22. PubMed ID: 23477710
[No Abstract] [Full Text] [Related]
4. The evolving treatment of ANCA-associated vasculitides.
Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and management of small vessel vasculitides].
Pettersson T; Karjalainen A
Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
[TBL] [Abstract][Full Text] [Related]
6. ANCA vasculitis: time for a change in treatment paradigm? Not yet.
Ntatsaki E; Mooney J; Watts RA
Rheumatology (Oxford); 2011 Jun; 50(6):1019-24. PubMed ID: 21292735
[TBL] [Abstract][Full Text] [Related]
7. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
Jayne D
Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
[No Abstract] [Full Text] [Related]
8. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA; Flores-Suárez LF
Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
[TBL] [Abstract][Full Text] [Related]
10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
11. [ANCA-associated vasculitis].
Holle JU
Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
[TBL] [Abstract][Full Text] [Related]
12. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
Clain JM; Specks U
Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713
[No Abstract] [Full Text] [Related]
13. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for ANCA-associated vasculitides.
Guillevin L
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
[TBL] [Abstract][Full Text] [Related]
15. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
Santana AN; Woronik V; Halpern AS; Barbas CS
J Bras Pneumol; 2011; 37(6):809-16. PubMed ID: 22241040
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
[TBL] [Abstract][Full Text] [Related]
17. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
18. [Uptodate in the management and treatment of ANCA-associated vasculitis].
Belaconi IN; Toma CL; Bogdan MA
Pneumologia; 2014; 63(2):78-80, 83-6. PubMed ID: 25241554
[TBL] [Abstract][Full Text] [Related]
19. [Allergo-immunology. Clinical immunology].
Chizzolini C
Rev Med Suisse; 2012 Jan; 8(323):11-3. PubMed ID: 22303732
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
